Theorem Clinical Research continues to broaden its ability to help sponsors optimize trial conduct
Theorem Clinical Research
continues to broaden its ability to help sponsors optimize trial conduct, recently implementing SAS® Clinical Data Integration (SAS CDI), an innovative solution that automates the process of transforming, managing and verifying the creation of industry-mandated data standards.
SAS enables Theorem to automate the mapping of standard electronic data capture (EDC) databases and external data into standard data sets that are compliant with the Clinical Data Interchange Standards Consortium (CDISC). By using the technology for routine tasks, Theorem can now more easily manage standards throughout the entire life cycle.
Additionally, SAS CDI will be leveraged to automate Theorem’s clinical data warehouse and highly visual data discovery tools, reducing time and effort to obtain clinical data in real time.
“As an early supporter of CDISC, Theorem recognized the value that standardization and harmonization would bring to clinical data and reporting,” said Mark Penniston, executive vice president of clinical analytics for Theorem. “Now we’re able to combine our deep experience in developing CDISC-compliant data domains with SAS technology to produce high-quality, standardized data sets faster and more efficiently.”
Kecia Serwin, vice president,
SAS Health Care and Life Sciences
, commented, “We’re delighted that Theorem has joined the list of leading life science organizations who’ve chosen SAS to streamline standards adoption in drug development processes.”
As a
CDISC Registered Solutions Provider,
Theorem was among the first global contract research organizations to execute a CDISC-compliant submission in 2004 and has created more than 50,000 CDISC-compliant data sets to date.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.